INTRODUCTION
Ampullary adenocarcinoma (AC) is a rare malignancy with limited evidence to guide systemic treatment in the metastatic setting.
METHODS
This post hoc analysis was conducted within the French national prospective FFCD-AC cohort, which enrolled patients undergoing curative-intent resection for localized AC...
E. Vo-Quang, V. Hautefeuille, O. Bouché et al.· European Journal of Cancer· 0 citations
RATIONALE-306 previously demonstrated improved overall survival (OS) in participants treated with tislelizumab plus chemotherapy versus those receiving placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma, with a minimum follow-up of approximately 15 months. Explo...
H. Yoon, Ken Kato, E. Raymond et al.· Nature Communications· 0 citations
First-line tislelizumab plus chemotherapy provided sustained and clinically meaningful efficacy benefits over placebo plus chemotherapy and was tolerable, with no new safety signals for patients with unresectable, locally advanced, or metastatic ESCC and PD-L1 TAP score ≥5%.
D. Tougeron, J. Xu, E. Raymond et al.· ESMO Open· 0 citations
High baseline circulating and tumor γδ T cells and early circulating CD8⁺PD-1⁺ T Cell expansion were associated with better outcome under AtezoBev, and an early induction of T cell-associated interferon-γ signaling at 3 weeks after the first injection of AtezoBev in patients that experienced response.
I. Galy-Fauroux, A. Asif-Laidin, M. Evain et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.